The Claim
In two animal models of cardiometabolic heart failure with preserved ejection fraction, administration of semaglutide was associated with improved left ventricular diastolic function, as indicated by a reduced E/e' ratio and lower left ventricular end-diastolic pressure, independent of weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In animal studies of a type of heart failure, a drug called semaglutide was linked to better relaxation of the heart's left ventricle during filling, measured by lower pressure and improved ultrasound markers, even when the animals did not lose weight.
See the scientific wording
In two animal models of cardiometabolic HFpEF, semaglutide was associated with improved left ventricular diastolic function, as measured by reduced E/e' ratio and lower left ventricular end-diastolic pressure, independent of weight loss.
A signaling molecule activates receptors on heart cells, which tells the cells to burn fat more efficiently and stop making new fat. This reduces fat buildup inside the heart muscle, which lessens stress on the cells and makes the heart wall more flexible, allowing it to relax and fill with blood more easily.
What the research says
1 studyIn animals with a stiff heart condition, a drug called semaglutide helped the heart relax better and fill with blood—even without making the animals lose weight. This suggests the drug might help humans with the same condition in a similar way.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.